Skip to Main Content

Good morning, everyone, and how are you today? We are doing just swell, thank you. The short person has left for the local schoolhouse, the official mascots are cozily snoozing in their corners, and we are quaffing a nice cup of stimulation. This, of course, means that the time has come to get cracking. No doubt, you can relate. So fire up your own coffee kettle and dig into the menu of tidbits assembled below. Meanwhile, we hope you have a productive day and invite you to remain in touch. We enjoy your suggestions, ideas, and criticisms …

Gilead Sciences (GILD) will pay up to $90 million over three years to Verily Life Sciences, an arm of computing giant Alphabet, to research immune cells in the hopes of finding new treatments for rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases, Forbes tells us. The hope is to identify which patients respond to existing drugs and to try to discover biological clues that could lead to new medicines. It will be the first large-scale use of Verily’s Immunoscape platform, which seeks to determine data and insights on the immunological nature of certain diseases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!